Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
$0.00
Program DescriptionLevodopa, the gold standard treatment for Parkinson’s disease (PD), is associated with a variety of complications and side effects including motor fluctuations and “OFF” periods. The armamentarium for OFF management is continually expanding, with 8 new therapies approved in just the past 6 years ranging from novel carbidopa-levodopa (C/L) formulations to a variety of adjunctive mechanisms. Availability of multiple therapies coupled with a lack of head-to-head comparisons presents a challenge to clinicians as to how to choose from among these options.
$0.00
Program DescriptionMultiple sclerosis (MS) management has been evolving at a staggering rate for the past two decades, with nearly a third of the 21 available disease modifying therapies (DMTs) receiving their FDA approvals in just the past few years. To assist practitioners in parsing out the rationale for and clinical utitity of these and other late-stage agents, Efficient surveyed five renowned MS specialists regarding their perspectives on these advances.
$0.00
OverviewWith the field’s increasing understanding of and ability to manipulate the complex networks of amyloid and tau that drive Alzheimer’s disease (AD), the value of directly visualizing their activity is exponentially rising. The implications for the future of AD diagnosis coupled with the rising potential that disease modifying therapies will reach routine clinical use corresponds to a potentially dramatic increase in the need for nuclear medicine (NM) in this field.
$0.00
Program Description Emotional blunting (EB) is one of the most highly reported and subjectively disruptive symptoms in patients with major depressive disorder (MDD). As EB can inhibit the ability to achieve full functional recovery in affected patients, proactive screening for and monitoring of this symptom are critical in helping patients achieve complete and sustained improvement in MDD. This CME initiative utilizes expert-led discussion to tackle common challenges and misconceptions in recognizing and resolving EB.
$0.00
OverviewAdvancements in the understanding of the pathophysiological mechanisms underlying multiple sclerosis (MS) have surged in recent years including increasing recognition that brain damage and subsequent disease worsening may occur earlier and more subtly than previously recognized. To date, there is no consensus regarding the relative roles of individual indicators of prognosis and/or disease worsening (e.g., brain atrophy, conventional MRI, cognitive impairment) in clinical decision-making.
$0.00
OverviewAcute ischemic stroke (AIS) is one of the leading causes of death and disability in the US. As a provider’s quick thinking and rapid actions are critical to patient outcomes, it is essential that clinicians are proficient and coordinated in optimized approaches to its management. But despite this need for cohesion, several elements of stroke work-up and treatment lack clear consensus and strategies are easily disrupted by challenges with clinic flow and variations in access/expertise.
$0.00
Program DescriptionThe care of Alzheimer’s disease (AD) is involved, multifaceted, and variable depending on individual patient preferences. With the introduction of novel tools and strategies for diagnosis and therapy, additional clinicians and responsibilities are being introduced into AD management each day. Though these developments are highly promising for patients, their integration is complicated by the wide breadth of providers in disparate practice locations/specialties that can be responsible for them.
$0.00
Alzheimer’s disease (AD) is a complex condition to diagnose and treat due to its significant overlap in symptoms and even pathological elements with other conditions. Notably, only half of AD cases are diagnosed and, when they are, diagnosis typically occurs several years following symptom onset. These issues only worsen for patients evaluated during earlier stages of AD. Now that disease-modifying therapies (DMT) specifically targeting early AD pathology are beginning to enter the therapeutic armamentarium, early diagnosis is becoming more critical than ever.
$0.00
Not only are cases of mild cognitive impairment (MCI) often not diagnosed, but more than 50% of these patients are misdiagnosed. One contributor to these observations is the fact that with biomarker assessments historically restricted (even in formal guidelines) to research, clinicians commonly rely on clinical scales, often with poor sensitivity to early stages, to generate suspicion of Alzheimer’s disease (AD).
$0.00
Due to the growing complexity in the management of Alzheimer’s disease (AD), patient care falls under a wide umbrella of clinical team members across specialties, increasing the complexity of disease management. As successful team-based care was a challenge even prior to the introduction of biomarkers and disease-modifying therapies to clinical practice, individual team member recognition of and proficiency in their changing roles and responsibilities is critical to ensure new strategies are executed effectively.